Literature DB >> 8264575

Effect of lacidipine on ischaemic and reperfused isolated rabbit hearts.

A Boraso1, A Cargnoni, L Comini, G Gaia, P Bernocchi, R Ferrari.   

Abstract

Lacidipine is a new developed dihydropyridine calcium-antagonist, showing a slow onset and long lasting-selective activity. To assess whether the administration of lacidipine protects the myocardium in a dose-dependent manner against ischaemia and reperfusion, isolated rabbit heart were infused with three different concentrations of lacidipine: 10(-10); 10(-9); 10(-8) M. Diastolic and developed pressures were monitored; coronary effluent was collected and assayed for CPK activity and for noradrenaline concentration; mitochondria were harvested and assayed for respiratory activity, ATP production and calcium content and tissue concentration of ATP, creatine phosphate (CP) and calcium were determined. Occurrence of oxidative stress during ischaemia and reperfusion was also monitored in terms of tissue content and release of reduced (GSH) and oxidized (GSSG) glutathione. Treatment with lacidipine at 10(-10) and 10(-9) M had no effects on the hearts when perfused under aerobic condition, whilst the higher dose reduced developed pressure of 36%. The ischaemic-induced deterioration of mitochondrial function was attenuated. On reperfusion treated hearts recovered better than the untreated hearts with respect to left ventricular performance, replenishment of ATP and CP stores and mitochondrial function. The reperfusion-induced tissue and mitochondrial calcium overload, release of CPK and of noradrenaline and oxidative stress were also significantly reduced. The effects of lacidipine were dose-dependent. The lower concentration (10(-10) M) failed to modify ischaemic and reperfusion damage. The dose of 10(-9) M was cardioprotective, but the best effect was found at 10(-8) M. It is concluded that lacidipine infusion provides a dose dependent protection of the heart against ischaemia and reperfusion. Because this protection occurred also at 10(-9) M, in the absence of negative inotropic effect during normoxia and of a coronary dilatory effect during ischaemia, it cannot be attributed to an energy sparing effect or to improvement of oxygen delivery. From our data we can envisage two other major mechanism: -1) membrane protection -2) reduction of oxygen toxicity. The ATP sparing effect occurring at 10(-8) M is likely to be responsable for the further protection.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8264575     DOI: 10.1007/bf00926837

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  45 in total

1.  Effectiveness of the once-daily calcium antagonist, lacidipine, in controlling 24-hour ambulatory blood pressure.

Authors:  M E Heber; P A Broadhurst; G S Brigden; E B Raftery
Journal:  Am J Cardiol       Date:  1990-11-15       Impact factor: 2.778

2.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

3.  Effects of diltiazem on the energy metabolism of the isolated rat heart submitted to ischaemia: a 31P NMR study.

Authors:  N Lavanchy; J Martin; A Rossi
Journal:  J Mol Cell Cardiol       Date:  1986-09       Impact factor: 5.000

Review 4.  Calcium channel antagonists, Part I: Fundamental properties: mechanisms, classification, sites of action.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1987-12       Impact factor: 3.727

5.  Proton and free oxygen radical interaction with the calcium transport system of cardiac sarcoplasmic reticulum.

Authors:  M L Hess; E Okabe; H A Kontos
Journal:  J Mol Cell Cardiol       Date:  1981-08       Impact factor: 5.000

6.  The beneficial effect of a calcium channel blocker, Diltiazem, on the ischemic-reperfused heart.

Authors:  R E Weishaar; R J Bing
Journal:  J Mol Cell Cardiol       Date:  1980-10       Impact factor: 5.000

7.  The effect of two different diltiazem treatments on infarct size in ischemic, reperfused porcine hearts.

Authors:  H H Klein; M Schubothe; K Nebendahl; H Kreuzer
Journal:  Circulation       Date:  1984-05       Impact factor: 29.690

8.  Inhibitory effect of calcium antagonists on the depletion of cardiac norepinephrine during postischemic reperfusion.

Authors:  W G Nayler; W J Sturrock
Journal:  J Cardiovasc Pharmacol       Date:  1985 May-Jun       Impact factor: 3.105

9.  Protective effect of early and late treatment with nifedipine during myocardial infarction in the conscious dog.

Authors:  J A Melin; L C Becker; G M Hutchins
Journal:  Circulation       Date:  1984-01       Impact factor: 29.690

Review 10.  Fundamental mechanisms of action of calcium antagonists in myocardial ischemia.

Authors:  W G Nayler; S Panagiotopoulos; J S Elz; W J Sturrock
Journal:  Am J Cardiol       Date:  1987-01-30       Impact factor: 2.778

View more
  4 in total

1.  Effects of felodipine on the ischemic heart: insight into the mechanism of cytoprotection.

Authors:  R Ferrari; A Cargnoni; P Bernocchi; G Gaia; M Benigno; E Pasini; P Pedersini; C Ceconi
Journal:  Cardiovasc Drugs Ther       Date:  1996-09       Impact factor: 3.727

2.  Anti-apoptotic effect of benidipine, a long-lasting vasodilating calcium antagonist, in ischaemic/reperfused myocardial cells.

Authors:  F Gao; B Gong; T A Christopher; B L Lopez; A Karasawa; X L Ma
Journal:  Br J Pharmacol       Date:  2001-02       Impact factor: 8.739

3.  Echinochrome A regulates phosphorylation of phospholamban Ser16 and Thr17 suppressing cardiac SERCA2A Ca²⁺ reuptake.

Authors:  Hyoung Kyu Kim; Jae Boum Youm; Seung Hun Jeong; Sung Ryul Lee; In-Sung Song; Tae Hee Ko; Julius Ryan Pronto; Kyung Soo Ko; Byoung Doo Rhee; Nari Kim; Bernd Nilius; Natalia P Mischchenko; Sergey A Fedoreyev; Valentin A Stonik; Jin Han
Journal:  Pflugers Arch       Date:  2014-11-21       Impact factor: 3.657

Review 4.  Lacidipine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of hypertension.

Authors:  C R Lee; H M Bryson
Journal:  Drugs       Date:  1994-08       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.